University of Auckland Lymphoedema Treatment Breakthrough: IGF Pathway Discovery Offers Hope

The Burden of Lymphoedema in New Zealand and Beyond

Lymphoedema, also spelled lymphedema in American English, is a chronic condition characterized by the accumulation of lymphatic fluid in tissues, leading to painful swelling, reduced mobility, and increased infection risk. The lymphatic system, a network of vessels and nodes parallel to the circulatory system, drains excess fluid from tissues back into the bloodstream. When damaged—often from cancer treatments like lymph node removal—it fails, causing persistent swelling primarily in limbs.

In New Zealand, approximately 20 percent of women undergoing breast cancer treatment with axillary lymph node dissection develop secondary lymphoedema. Globally, it affects millions, with prevalence rates post-breast cancer surgery ranging from 7 to 38 percent in local studies. Primary lymphoedema, congenital in nature, is rarer at about 1 in 6,000 births. This incurable condition demands lifelong management, straining healthcare systems and patients' quality of life.

Patients face emotional and physical tolls: recurrent cellulitis infections, fibrosis, and psychological distress. In Aotearoa, where breast cancer incidence rises, addressing lymphoedema through innovative research is critical for public health.

University of Auckland's Groundbreaking IGF Discovery

Researchers at Waipapa Taumata Rau, University of Auckland, have identified a novel pathway involving insulin-like growth factor (IGF) signaling that drives lymphangiogenesis—the formation and growth of lymphatic vessels. This breakthrough, detailed in a recent Cell Reports publication, reveals IGF as a potent stimulator of lymphatic endothelial cell proliferation and vessel sprouting.

The study demonstrates that activating IGF receptors accelerates lymphatic development in vivo, offering a mechanistic target to regenerate damaged vessels in lymphoedema patients. Previously unknown in this context, IGF intersects metabolic and growth signaling to bolster vascular repair.

From Zebrafish Models to Human Relevance: The Research Journey

Leveraging zebrafish (Danio rerio) as a model organism, the team fluorescently labeled lymphatic vessels red and blood vessels green, enabling real-time imaging of vessel growth in transparent larvae. Zebrafish develop rapidly, mirroring human lymphatic biology closely, allowing observation without disrupting embryogenesis.

• Genetic manipulation upregulated IGF signaling, resulting in hyperbranched lymphatic networks.
• Inhibitors confirmed pathway specificity, reducing vessel density.
• Human lymphatic endothelial cells cultured in vitro responded similarly, sprouting new vessels upon IGF exposure.

This translational bridge—from fish to human cells—validates the pathway's therapeutic potential. Ethical approvals from the University of Auckland Animal Ethics Committee ensured rigorous standards.

For aspiring researchers, such models exemplify interdisciplinary approaches in higher education, blending genetics, imaging, and cell biology. Explore research jobs at institutions like UoA to contribute to similar innovations.

The Research Team: Pioneers in Molecular Medicine

Dr. Jonathan Astin, senior lecturer in the Department of Molecular Medicine and Pathology, led the effort. "Our group has discovered a new molecule and pathway that together promote lymphatic vessel growth," Astin noted, emphasizing its medical relevance.

Key contributors included Dr. Wenxuan Chen (doctoral student), Dr. Justin Rustenhoven (senior research fellow), Dr. Kate Lee, and Professor Stefan Bohlander, all from UoA's Faculty of Medical and Health Sciences. US collaborators extended human cell validations. Their synergy highlights collaborative higher ed environments fostering breakthroughs.

This publication underscores UoA's research prowess, attracting talent via higher ed jobs in New Zealand.

Cell Reports Publication: Elevating NZ Research Profile

Published in Cell Reports (DOI: 10.1016/j.celrep.2026.116971), the paper "Insulin-like growth factor signaling regulates zebrafish lymphatic-vessel development" garners attention for mechanistic novelty. Cell Reports, a high-impact open-access journal, amplifies UoA's global visibility.

In NZ's competitive research landscape, such outputs secure funding and partnerships. For academics, publishing here boosts careers—check higher ed career advice for tips.

Current Lymphoedema Treatments: Effective but Limited

Standard care—Complete Decongestive Therapy (CDT)—encompasses manual lymphatic drainage (MLD), multilayer compression bandaging, skin care, and exercise. Intermittent pneumatic compression devices aid fluid movement. Yet, no curative option exists; treatments are palliative, time-intensive, and prone to recurrence.

• Compression garments: Daily wear, uncomfortable long-term.
• MLD: Requires skilled therapists, 45-60 min sessions.
• Surgery (e.g., lymph node transfer): Experimental, variable success.

Challenges include patient adherence, costs, and progression despite therapy. IGF offers a paradigm shift toward regeneration.

Toward Clinical Translation: Mouse Models and Beyond

Next phases: Testing IGF agonists in lymphoedema-induced mice to assess vessel regrowth and symptom reduction. Success could spur clinical trials for topical/systemic delivery, minimizing side effects.

UoA's ecosystem, including the Auckland Bioengineering Institute (ABI), supports this via smart garments for personalized compression (Dr. Massi Hesam) and predictive modeling (Dr. Hayley Reynolds).

UoA's Role in New Zealand Higher Education Research

Waipapa Taumata Rau leads NZ vascular biology, with Marsden Fund and MBIE Smart Ideas grants fueling lymphoedema projects. This aligns with national priorities in cancer survivorship and biotech.Explore NZ university opportunities.

From genomics labs to bioengineering, UoA trains next-gen scientists. University jobs in research proliferate here.

Career Opportunities in Lymphatic and Vascular Research

This discovery spotlights demand for experts in developmental biology, pharmacology, and translational medicine. PhD/postdoc roles at UoA offer hands-on zebrafish/human models experience. Lecturers in molecular pathology thrive amid such impacts.

• Research assistantships: Genetic screening, imaging.
• Postdocs: Therapy development.
• Faculty: Leading labs like Astin's.

Visit research jobs, postdoc positions, and academic CV tips to join.

Photo by Alex Shute on Unsplash

Future Horizons: Integrating IGF into Broader Therapies

Beyond lymphoedema, IGF may aid wound healing, transplant rejection, and obesity-related issues. NZ's research ecosystem, bolstered by UoA, positions Aotearoa as a lymphatics hub. Ongoing trials and collaborations promise accelerated timelines.

For patients and professionals, this instills hope. Engage with Rate My Professor for insights into UoA faculty or higher ed jobs to advance the field.